Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas
(PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor
prognosis with progression-free survival of around 13 weeks and median overall survival of
approximately 20 weeks after second line chemotherapy. Recent studies suggest that albumin
may be preferentially concentrated in pancreatic cancers that appear to be starved for this
protein. Thus, any molecule attached to albumin would also collect inside the tumor. Based on
its postulated mechanism of action, INNO-206 may improve the activity of doxorubicin without
increasing its toxicity, as has been demonstrated in animal studies, and induce enhanced
anti-tumor efficacy.